Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is an iodinated contrast agent presented as an injectable solution for intraarterial and intravenous use. It enhances radiographic imaging by increasing the radiodensity of vascular and tissue structures during diagnostic procedures.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Optiray (ioversol) is used as an iodinated contrast medium in radiographic imaging procedures.

- Angiography: provides clear visualization of blood vessels and vascular anatomy. - Computed tomography (CT) imaging: enhances contrast between soft tissues, facilitating accurate diagnosis. - Contrast‑enhanced radiographic examinations: improves detection of lesions and delineates organ structures.

Adverse reactions to Optiray may range from mild to severe and are related to its iodine content and osmolarity.

Common Side Effects: - Nausea: transient feeling of sickness after injection. - Warm sensation: brief feeling of heat or flushing. - Metallic taste: temporary metallic aftertaste in the mouth. - Headache: mild to moderate headache post‑administration. - Vomiting: occasional emesis following contrast exposure. - Injection site pain: mild discomfort at the site of administration.

Serious or Rare Side Effects: - Anaphylactoid reaction: severe allergic response that can be life‑threatening. - Severe hypotension: sudden drop in blood pressure requiring monitoring. - Acute kidney injury: renal function impairment, especially in at‑risk patients. - Cardiac arrhythmia: irregular heart rhythms observed during or after injection. - Pulmonary edema: fluid accumulation in the lungs, a rare emergency. - Seizures: neurologic events occurring in susceptible individuals.

Prior to using Optiray, clinicians should evaluate patient-specific factors and follow safe handling practices.

- Renal function assessment: verify baseline kidney function to reduce risk of nephrotoxicity. - Allergy history: screen for prior iodine or contrast media reactions. - Use lowest effective dose: limit exposure while achieving diagnostic quality. - Monitor vital signs: observe blood pressure and heart rate during administration. - Avoid in patients with severe iodine allergy: contraindicated unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Optiray may interact with other medications, influencing safety or efficacy.

Major Interactions (Avoid): - Concurrent high‑osmolar contrast agents: increase risk of renal injury. - Loop diuretics in renal impairment: may exacerbate kidney dysfunction. - Metformin in reduced kidney function: risk of lactic acidosis. - ACE inhibitors in hypotensive patients: potentiate blood pressure drops. - Radioactive iodine therapy: interfere with iodine balance.

Moderate Interactions (Monitor Closely): - Non‑ionic contrast agents: cumulative iodine load. - Antihistamines: may mask early allergic signs. - Beta‑blockers: affect cardiovascular response. - Calcium channel blockers: influence blood pressure stability. - NSAIDs: add renal stress when combined with contrast.